P Rothe1, M Kalchthaler, S Mühlich. 1. Gesellschaft für Klinische Studien, Vituro GmbH, Käthe-Kollwitz-Straße 9, 04109, Leipzig, Deutschland. info@vituro.de
Abstract
BACKGROUND: Epidemiological data demonstrate an increasing prevalence of symptoms of overactive bladder (OAB) with age not only in women, but especially in men. Despite a comparable prevalence, however, men are still highly underrepresented in most large randomized studies on the effect of antimuscarinic drugs. QUESTION: In this subgroup analysis of the CAP Study the efficacy and tolerability of solifenacin was examined in 111 men with symptoms of OAB. The study was performed in a network between general practitioners and urologists under routine conditions over a period of 12 months. RESULTS: Treatment with solifenacin reduced all symptoms of OAB significantly, and the use of pads decreased by more than half. The tolerability of therapy was judged as "excellent" or "good" by over 95% of doctors and patients. CONCLUSION: This subgroup analysis of the CAP Study confirms the good efficacy and tolerability of solifenacin in male OAB in daily practice over a treatment period of 1 year.
BACKGROUND: Epidemiological data demonstrate an increasing prevalence of symptoms of overactive bladder (OAB) with age not only in women, but especially in men. Despite a comparable prevalence, however, men are still highly underrepresented in most large randomized studies on the effect of antimuscarinic drugs. QUESTION: In this subgroup analysis of the CAP Study the efficacy and tolerability of solifenacin was examined in 111 men with symptoms of OAB. The study was performed in a network between general practitioners and urologists under routine conditions over a period of 12 months. RESULTS: Treatment with solifenacin reduced all symptoms of OAB significantly, and the use of pads decreased by more than half. The tolerability of therapy was judged as "excellent" or "good" by over 95% of doctors and patients. CONCLUSION: This subgroup analysis of the CAP Study confirms the good efficacy and tolerability of solifenacin in male OAB in daily practice over a treatment period of 1 year.
Authors: Paul Abrams; Linda Cardozo; Magnus Fall; Derek Griffiths; Peter Rosier; Ulf Ulmsten; Philip van Kerrebroeck; Arne Victor; Alan Wein Journal: Neurourol Urodyn Date: 2002 Impact factor: 2.696
Authors: C R Chapple; R Martinez-Garcia; L Selvaggi; P Toozs-Hobson; W Warnack; T Drogendijk; D M Wright; J Bolodeoku Journal: Eur Urol Date: 2005-09 Impact factor: 20.096
Authors: Mickey M Karram; Marc R Toglia; Scott R Serels; Masakazu Andoh; Allam Fakhoury; Sergio Forero-Schwanhaeuser Journal: Urology Date: 2008-11-08 Impact factor: 2.649
Authors: Alexander Roosen; Christopher R Chapple; Roger R Dmochowski; Clare J Fowler; Christian Gratzke; Claus G Roehrborn; Christian G Stief; Karl-Erik Andersson Journal: Eur Urol Date: 2009-08-04 Impact factor: 20.096
Authors: Joshua S Benner; Michael B Nichol; Eric S Rovner; Zhanna Jumadilova; Jose Alvir; Mohamed Hussein; Kristina Fanning; Jeffrey N Trocio; Linda Brubaker Journal: BJU Int Date: 2009-11-12 Impact factor: 5.588